Benralizumab
Mechanism :
It is an Interleukin-5 (IL-5) Inhibitor available as a monoclonal antibody and is used as immunotherapy.
Indication :
- Indicated for add-on maintenance treatment of severe asthma in patients with an eosinophilic phenotype aged ≥12 years
Contraindications :
- It is to be avoided in patients with a history of hypersensitivity to benralizumab. Use with caution in patients with hamster protein hypersensitivity, as the drug is produced in Chinese hamster ovary cells.
- Benralizumab should not be used to treat acute bronchospasm or status asthmaticus.
- Benralizumab reduces the production and survival of eosinophils, which may be involved in the immunological response to some helminth infections. Hence treat worm infestation first before starting benralizumab.
Dosing :
It is available as a injection (1 mL = 30 mg) to be given subcutaneously.
<12 years:
Safety and efficacy not established.
≥12 years:
30 mg SC every 4 weeks for the first 3 doses, and then to be given every 8 weeks(Max dose: 30 mg/dose).
Adverse Effect :
Headache, pharyngitis, fever, hypersensitivity reactions
Interaction :
There are no drug interactions associated with Benralizumab.
Pediatric Oncall
08/09/2024 21:34:35
08/09/2024 21:34:35
Benralizumab